Efficacy and Safety of Octreotide Combined with Conventional Therapy in Alleviating MBO ：a Meta-analysis
- VernacularTitle:奥曲肽联合常规治疗用于缓解恶性肠梗阻有效性与安全性的Meta分析
- Author:
Jiawei XU
1
;
Bingqian LIANG
1
;
Jiansheng GUO
2
Author Information
1. Dept. of General Surgery，the First Clinical College of Shanxi Medical University，Taiyuan 030001，China
2. Dept. of General Surgery，the First Hospital of Shanxi Medical University，Taiyuan 030001，China
- Publication Type:Journal Article
- Keywords:
Octreotide;
Malignant bowel obstruction;
Effectiveness;
Safety;
Meta-analysis
- From:
China Pharmacy
2019;30(22):3138-3143
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To systematically evaluate the efficacy and safety of octreotide combined with conventional therapy in alleviating malignant bowel obstruction （MBO）， and provide evidence-based reference for clinical medication. METHODS： Retrieved from Cochrane Library， PubMed， Embase， CNKI， Wanfang database and Google academic， RCTs about octreotide combined with conventional therapy （trial group） vs. conventional therapy （control group） for relieving MBO were collected. After literature screening， data extraction and quality evaluation with Cochrane system evaluator manual 5.0 risk evaluation tool， Meta-analysis was conducted by using Rev Man 5.3 statistical software. RESULTS： A total of 13 items of RCT were included， with a total of 850 patients. Meta-analysis results showed that total response rate of trial group was significantly higher than control group [OR＝5.30，95％CI（3.47，8.10），P＜0.000 01]. Results of subgroup analysis showed that total response rate of single administration patients [OR＝6.88，95％CI（3.22，4.68），P＜0.000 01] and continuous administration patients [OR＝4.60， 95％CI（2.76，7.68）， P＜0.000 01] in trial group were significantly higher than control group. The abdominal distension relief time [MD＝－3.92， 95％CI（－4.15， －3.70）， P＜0.000 01]， abdominal pain relief time [MD＝－3.37， 95％CI（－3.61，－3.14）， P＜0.000 01]， nausea and vomiting relief time [MD＝－2.46， 95％CI（－2.81，－2.21）， P＜0.000 01] and exhaust relief time [MD＝－2.88， 95％CI（－3.31， －2.46）， P＜0.000 01] in trial group were significantly shorter than control group. Subgroup analysis of exhaust relief time showed that exhaust relief time of single administration patients [MD＝－2.90，95％CI（－3.48，－2.32），P＜0.000 01] and continuous administration patients [MD＝－2.71， 95％CI（－3.14，－2.29）， P＜0.000 01] in trial group were significantly shorter than control group. After treatment， the gastrointestinal decompression volume （P＜0.05） and the incidence of ADR [OR＝0.28，95％CI（0.13，0.62），P＝0.001] in trial group were significantly lower than in control group. CONCLUSIONS： Octreotide combined with conventional treatment is safe and effective in alleviating MBO.
